MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530484 | Name: CNX-011-67

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CNX-011-67 is a highly potent and selective small molecule agonist with an EC50 of 0.24 nM towards human GPR40. CNX-011-67 suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro. CNX-011-67 enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.

Chemical Structure

CNX-011-67
CNX-011-67
CAS#Unknown

Theoretical Analysis

MedKoo Cat#: 530484

Name: CNX-011-67

CAS#: Unknown

Chemical Formula:

Exact Mass:

Molecular Weight:

Elemental Analysis:

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
CNX-011-67; CNX011-67; CNX 011-67; CNX-01167; CNX01167; CNX 01167.
IUPAC/Chemical Name
unknow.
InChi Key
InChi Code
SMILES Code
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sunil V, Verma MK, Oommen AM, Sadasivuni M, Singh J, Vijayraghav DN, Chandravanshi B, Shetty J, Biswas S, Dandu A, Moolemath Y, Venkataranganna MV, Somesh BP, Jagannath MR. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. BMC Pharmacol Toxicol. 2014 Mar 25;15:19. doi: 10.1186/2050-6511-15-19. PubMed PMID: 24666736; PubMed Central PMCID: PMC3994293. 2: Verma MK, Biswas S, Chandravanshi B, Neelima K, Oommen AM, Jagannath MR, Somesh BP. A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro. BMC Res Notes. 2014 Sep 3;7:595. doi: 10.1186/1756-0500-7-595. PubMed PMID: 25186493; PubMed Central PMCID: PMC4161845. 3: Gowda N, Dandu A, Singh J, Biswas S, Raghav V, Lakshmi MN, Shilpa PC, Sunil V, Reddy A, Sadasivuni M, Aparna K, Verma MK, Moolemath Y, Anup MO, Venkataranganna MV, Somesh BP, Jagannath MR. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats. BMC Pharmacol Toxicol. 2013 May 21;14:28. doi: 10.1186/2050-6511-14-28. PubMed PMID: 23692921; PubMed Central PMCID: PMC3668190. 4: Verma MK, Sadasivuni MK, Yateesh AN, Neelima K, Mrudula S, Reddy M, Smitha R, Biswas S, Chandravanshi B, Pallavi PM, Oommen AM, Jagannath MR, Somesh BB. Activation of GPR40 attenuates chronic inflammation induced impact on pancreatic β-cells health and function. BMC Cell Biol. 2014 Jun 30;15:24. doi: 10.1186/1471-2121-15-24. PubMed PMID: 24974801; PubMed Central PMCID: PMC4083038. 5: Li Z, Qiu Q, Geng X, Yang J, Huang W, Qian H. Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Expert Opin Investig Drugs. 2016 Aug;25(8):871-90. doi: 10.1080/13543784.2016.1189530. PubMed PMID: 27171154.